Switch theme
Sign up to access all valuation multiples
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine and genetic engineering drugs products. It is also engaged in the wholesale, retail and distribution business of Chinese and western medicine, Chinese herbal medicine, medical apparatus, and instruments. The main business of the company is divided into pharmaceutical business sales and the industry of pharmaceutical. The product portfolio of the company includes Corbrin capsule, Cymusi, New Cyspin, Kasiping, Panlisu, Acarbose, and others.
1993
14.1K+
LTM Revenue $6.0B
LTM EBITDA $757M
$10.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Huadong Medicine has a last 12-month revenue (LTM) of $6.0B and a last 12-month EBITDA of $757M.
In the most recent fiscal year, Huadong Medicine achieved revenue of $5.8B and an EBITDA of $729M.
Huadong Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Huadong Medicine valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.0B | XXX | $5.8B | XXX | XXX | XXX |
| Gross Profit | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Margin | 33% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $757M | XXX | $729M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $637M | XXX | $643M | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $512M | XXX | $487M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Huadong Medicine's stock price is CNY 45 (or $6).
Huadong Medicine has current market cap of CNY 78.4B (or $10.9B), and EV of CNY 77.4B (or $10.7B).
See Huadong Medicine trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.7B | $10.9B | XXX | XXX | XXX | XXX | $0.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Huadong Medicine has market cap of $10.9B and EV of $10.7B.
Huadong Medicine's trades at 1.8x EV/Revenue multiple, and 14.7x EV/EBITDA.
Equity research analysts estimate Huadong Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Huadong Medicine has a P/E ratio of 21.2x.
See valuation multiples for Huadong Medicine and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.9B | XXX | $10.9B | XXX | XXX | XXX |
| EV (current) | $10.7B | XXX | $10.7B | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 14.2x | XXX | 14.7x | XXX | XXX | XXX |
| EV/EBIT | 16.8x | XXX | 16.7x | XXX | XXX | XXX |
| EV/Gross Profit | 5.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 22.3x | XXX | XXX | XXX |
| EV/FCF | 33.9x | XXX | 38.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHuadong Medicine's last 12 month revenue growth is 7%
Huadong Medicine's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Huadong Medicine's rule of 40 is 18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Huadong Medicine's rule of X is 31% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Huadong Medicine and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 18% | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Huadong Medicine acquired XXX companies to date.
Last acquisition by Huadong Medicine was XXXXXXXX, XXXXX XXXXX XXXXXX . Huadong Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Huadong Medicine founded? | Huadong Medicine was founded in 1993. |
| Where is Huadong Medicine headquartered? | Huadong Medicine is headquartered in China. |
| How many employees does Huadong Medicine have? | As of today, Huadong Medicine has 14.1K+ employees. |
| Is Huadong Medicine publicy listed? | Yes, Huadong Medicine is a public company listed on SHE. |
| What is the stock symbol of Huadong Medicine? | Huadong Medicine trades under 000963 ticker. |
| When did Huadong Medicine go public? | Huadong Medicine went public in 2000. |
| Who are competitors of Huadong Medicine? | Similar companies to Huadong Medicine include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Huadong Medicine? | Huadong Medicine's current market cap is $10.9B |
| What is the current revenue of Huadong Medicine? | Huadong Medicine's last 12 months revenue is $6.0B. |
| What is the current revenue growth of Huadong Medicine? | Huadong Medicine revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Huadong Medicine? | Current revenue multiple of Huadong Medicine is 1.8x. |
| Is Huadong Medicine profitable? | Yes, Huadong Medicine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Huadong Medicine? | Huadong Medicine's last 12 months EBITDA is $757M. |
| What is Huadong Medicine's EBITDA margin? | Huadong Medicine's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Huadong Medicine? | Current EBITDA multiple of Huadong Medicine is 14.2x. |
| What is the current FCF of Huadong Medicine? | Huadong Medicine's last 12 months FCF is $316M. |
| What is Huadong Medicine's FCF margin? | Huadong Medicine's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Huadong Medicine? | Current FCF multiple of Huadong Medicine is 33.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
